Folfox
Folfox 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
5 项
已进入 III/IV 期
22 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Bristol-Myers Squibb
- Fudan University
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Rutgers, The State University of New Jersey
- Taizhou Mabtech Pharmaceutical Co.,Ltd
- Michael J Cavnar, MD
- Shanghai Pudong Hospital
- Hunan Cancer Hospital
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、澳大利亚、法国、爱尔兰、意大利、Romania、South Korea、西班牙、英国、加拿大、德国
正在招募患者的 Folfox 研究
Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
II 期招募中中国NCT06121700Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
II 期招募中中国NCT07806292sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
II 期招募中美国NCT05332002Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
III 期招募中中国NCT07595276Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
II 期招募中美国NCT07201519Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial
II 期招募中中国NCT07106034Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
II 期招募中中国NCT06406634Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
II 期招募中中国NCT05751343Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
II 期招募中中国NCT07127822A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer
II 期招募中中国NCT07562490HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC
不适用招募中中国NCT06632093Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
II 期招募中中国NCT07025174SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer
I 期招募中美国NCT05412082CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
I 期 / II 期招募中美国澳大利亚法国爱尔兰NCT07335497BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
I 期 / II 期招募中美国加拿大德国爱尔兰NCT04421820Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer
II 期招募中中国NCT06856187Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)
III 期招募中South KoreaNCT05534087FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis
II 期招募中中国NCT06988852Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer
III 期招募中RussiaNCT06226857Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
不适用招募中加拿大NCT05068531Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis
II 期招募中加拿大NCT06225843A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
I 期招募中美国澳大利亚加拿大丹麦NCT04929223mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
III 期招募中美国Puerto RicoNCT05677490Induction Chemotherapy for Locally Recurrent Rectal Cancer
III 期招募中比利时荷兰挪威PortugalNCT04389086
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。